About Kintor Pharma
- Time of issue:2019-04-14 00:00:00
Founded in 2009, Kintor Pharma focuses on developing innovative small molecules and biologic drugs for androgen-related diseases with significant unmet needs, including treatments for COVID-19 prostate cancer, breast cancer, liver cancer, alopecia, acne and other conditions.
On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
Kintor Pharma's product pipeline includes innovative small molecule drugs, biologics, and combination therapies. The product pipeline consists of seven products undergoing clinical research, including androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR inhibitor, Hedgehog/SMO inhibitor, AR-PROTAC and PD-L1/TGF-β dual-targeting antiobdy. The company also has ongoing preclinical programs in ALK-1/VEG dual-targeting antibody and c - Myc inhibitors.
Kintor Pharma has been granted more than 80 patents worldwide. Many of the company's projects were listed as National Special Projects for Significant Novel Drugs Development during the 12th (2011-2015) and 13th (2016-2020) Five-Year Plans.
Kintor Pharma's lead product, proxalutamide, is undergoing clinical trials in the world including China and the United States for the treatment of COVID-19 infection, Metastatic Castration-Resistant Prostate Cancer (mCRPC) and metastatic breast cancer.
In August 2020, Kintor Pharma announced that the capitalization of its Suzhou Industrial Park research and development (R&D) center and manufacturing facility. The facility covers some 20,000 square meters. Designed to meet all of Kintor Pharma's manufacturing needs, the facility was designed and constructed using state-of-the-art technologies and complies with international good manufacturing practices (GMP) standards.
Kintor Pharms's management team has extensive experience in the research and development of novel drugs and the management of start-up pharmaceutical companies. Under their leadership, the company has attracted a group of outstanding domestic and foreign professionals experienced with managing all aspects of drug development and leading multinational pharmaceutical companies.
Scan the QR code to read on your phone